Claim 1: a inmunoconjugado comprising an Antibody that binds to CD22 joined by Covalent bond to a cytotoxic Agent,Where the Antibody binds to an epitope within the 20 amino acids to 240 SEC ID no. 28 and the cytotoxic Agent is a Derivative of nemorrubicina.4: The inmunoconjugado Claim of claim 1 in which the Antibody comprises: (a) (i) - H1 HVR comprising the amino acid sequence of sec id no. 9； (ii) comprising the HVR H2No amino acid SEC ID no. 10； (iii) HVR - H3 comprising the amino acid sequence of sec id no. 11； (iv) HVR - L1 comprising an Amino Acid Sequence selected SEC ID no. 12 and 1522； (V) - HVR L2 comprising the amino acid sequence of sec id no. 13； and (VI) HVR - L3 comprising the amino acid sequence of sec id no. 14； or (b) (i) - HVR H1 which comprises the sequence of AminO u00e1cidos SEC ID no. 9, (ii) - H2 HVR comprising the amino acid sequence of sec id no. 10, (iii) HVR - H3 comprising the amino acid sequence of sec id no. 11(iv) HVR - L1 comprising the amino acid sequence of sec id no. 15(V) - HVR L2 comprising the amino acid sequence of sec id no. 13 and (VI) HVR - L3 comprising the amino acid sequence of sec id no. 14.Claim 28: a Pharmaceutical formulation comprising the inmunoconjugado of any of the preceding Claims, and a pharmaceutically acceptable Carrier.Claim 30: a method for treating an individual who has cancer CD22 positiveThe Method comprises administering to the individual an effective amount of inmunoconjugado of any of claims 1 to 27.Claim 48: a method for treating an individual who has to CD22 positive cancer, where the Cancer CD22 positive Express p-gp.The Method comprises administering to the individual an effective amount of inmunoconjugado of any of claims 1 to 27.Reivindicación 1: Un inmunoconjugado que comprende un anticuerpo que se une a CD22 unido por enlace covalente a un agente citotóxico, en donde el anticuerpo se une a un epítopo dentro de los aminoácidos de 20 a 240 de SEC ID Nº 28 y en donde el agente citotóxico es un
